SYS6006

BIOLOGICAL3 trials

Sponsors

Jiangsu Province Centers for Disease Control and Prevention, CSPC Megalith Biopharmaceutical Co.,Ltd.

Conditions

Advanced Solid TumorsCOVID-19SARS-CoV-2 Infection

Phase 1

SYS6006 in Combination With Enlonstobart Injection Versus Enlonstobart Injection in Participants With Advanced Solid Tumors

Not yet recruitingNCT07622225

CSPC Megalith Biopharmaceutical Co.,Ltd.Advanced Solid Tumors

Start: 2026-05-29End: 2030-01-31Target: 264Updated: 2026-06-03

Phase 4

Effectiveness of a Second COVID-19 Vaccine Booster in Chinese Adults

Jiangsu Province Centers for Disease Control and PreventionCOVID-19

Start: 2023-05-18End: 2024-12-31Target: 10000Updated: 2023-05-22

Immunogenicity and Safety of a Single Dose of mRNA SARS-CoV-2 Vaccine in Chinese Adults With Hybrid Immunity

CompletedNCT07834073

Jiangsu Province Centers for Disease Control and PreventionCOVID-19, SARS-CoV-2 Infection

Start: 2023-05-23End: 2024-02-28Updated: 2026-09-22

Related Papers

Effectiveness of a booster dose of aerosolized or intramuscular adenovirus type 5 vectored COVID-19 vaccine in adults: a multicenter, partially randomized, platform trial in China.

2025-03-263 citations